摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-methyl-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol | 1373863-94-5

中文名称
——
中文别名
——
英文名称
(5-methyl-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol
英文别名
[5-methyl-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]methanol
(5-methyl-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol化学式
CAS
1373863-94-5
化学式
C9H10F3NO2
mdl
——
分子量
221.179
InChiKey
CJNNGFPJJIVBDX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    42.4
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
    [FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
    摘要:
    本发明涉及吡唑并吡啶衍生物,这些衍生物具有阻断TTX-S型电压门控钠通道的活性,并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
    公开号:
    WO2014068988A1
  • 作为产物:
    描述:
    5-methyl-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylic acid 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以96%的产率得到(5-methyl-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methanol
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
    [FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
    摘要:
    本发明涉及吡唑并吡啶衍生物,这些衍生物具有阻断TTX-S型电压门控钠通道的活性,并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
    公开号:
    WO2014068988A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINONE EN TANT QUE BLOQUANTS DES TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2013161312A1
    公开(公告)日:2013-10-31
    The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及吡咯吡啶酮衍生物,这些衍生物TTX-S型电压门控通道具有阻断作用,并且在治疗或预防涉及电压门控通道的疾病和障碍中具有用途。发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗涉及电压门控通道的疾病中的使用。
  • [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2012053186A1
    公开(公告)日:2012-04-26
    The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及具有对电压门控通道(如TTX-S通道)具有阻塞活性的芳基酰胺衍生物,用于治疗或预防涉及电压门控通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控通道的这类疾病中使用这些化合物和组合物。
  • [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
    申请人:IFM DUE INC
    公开号:WO2022015975A1
    公开(公告)日:2022-01-20
    This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    本公开涉及化学实体(例如,化合物或药用盐,和/或合物,和/或共晶,和/或该化合物的药物组合),其抑制(例如,拮抗)干扰素基因激活剂(STING)。所述化学实体可用于治疗某种疾病、疾病或疾病,其中增加(例如,过多)STING激活(例如,STING信号传导)导致病理和/或症状和/或该疾病、疾病或疾病的进展(例如,癌症)在受试者(例如,人类)中。本公开还涉及包含相同化学实体的组合物,以及使用和制备相同的方法。
  • ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS
    申请人:Yamagishi Tatsuya
    公开号:US20140336377A1
    公开(公告)日:2014-11-13
    The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及一种芳基酰胺衍生物,其具有阻断电压门控通道(如TTX-S通道)的活性,并且在涉及电压门控通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控通道的这种疾病的预防或治疗中的使用。
  • PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS
    申请人:RaQualia Pharma Inc.
    公开号:US20150094306A1
    公开(公告)日:2015-04-02
    The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及吡咯吡啶酮衍生物,其具有阻断电压门控通道(如TTX-S通道)的活性,并且在治疗或预防涉及电压门控通道的疾病和疾病方面非常有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及电压门控通道的疾病方面使用这些化合物和组合物。
查看更多